Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

TRECing down the source: naive and memory T cell generation in dirty mice and men (2026) Derksen LY, de Dios Panal ES, Brouwers TM, Sanal E, Schuren AB, Westera L, van den Berg SP, et al. Journal article Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS) (2026) Deroose CM, Leupe H, Hicks RJ, Virgolini I, Braat AJ, Mittra ES, Albert NL, et al. Journal article, Review article [177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial (2026) Ferone D, Pavel ME, Herrmann K, Kunz PL, Myrehaug S, Halperin D, Chasen B, et al. Journal article Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study (2026) Vogel A, Ben Khaled N, Ramirez JR, Marhenke S, Siegler G, Siebler J, Lindig U, et al. Journal article [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial (2026) Walter T, Jann H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teulé A, Baum RP, et al. Journal article Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas (2026) Hernandez-Felix JH, Golagha M, Jha A, Varghese D, Grozinsky-Glasberg S, Riechelmann R, Fazio N, et al. Journal article, Review article Influence of Sample Preparation Methods for Porcine Tissue: Calibration-Free LIBS for In Vivo Applications (2026) Böhmer E, Thoma OM, Waldner M, Klämpfl F, Schmidt M, Hohmann M Journal article Clinical presentation and outcomes of sporadic neuroendocrine neoplasms in young adults (2026) Malczewska-Herman A, Rinke A, Holmager P, Opalińska M, McNamara MG, Netto D, Tesselaar ME, et al. Journal article Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial (2026) Atreya R, Kühbacher T, Vieth M, Jefremow A, Hirschmann S, Waldner M, Fischer S, et al. Journal article Authors’ response to letter to editor—silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis (2026) Atreya R, Neurath M Journal article